Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

Insider Monkey2024-12-31

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2495508368?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-31 04:11","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2495508368","market":"us","top_or_hot":-1,"title":"Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?","media":"Insider Monkey","content":"<div>\n<p>We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-editas-medicine-inc-edit-201112515.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-31 04:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-editas-medicine-inc-edit-201112515.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-editas-medicine-inc-edit-201112515.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"USJW.SI","symbol_name":"ALPHAB 3xLongSG261006","start_time":0,"source_url":"https://finance.yahoo.com/news/why-editas-medicine-inc-edit-201112515.html","article_id":"2495508368","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495508368","pubTimestamp":1735589472,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently compiled a list of the Top 11 CRISPR Stocks to Invest In.In this article, we are going to take a look at where Editas Medicine, Inc.  stands against the other CRISPR stocks.The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital therapeutics, and artificial intelligence. Among the most exciting breakthroughs are gene therapy and gene editing, with CRISPR-Cas9 leading the charge. This remarkable tool, inspired by bacteria's natural defenses, acts like precise genetic scissors—faster, cheaper, and more accurate than other genome-editing methods.The regulatory landscape for gene and regenerative therapies has also come a long way. In the U.S., the FDA has created clearer pathways for development, aided by the Regenerative Medicine Advanced Therapy  designation, which speeds up revie","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"USJW.SI":"ALPHAB 3xLongSG261006","EDIT":"Editas Medicine, Inc.","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4588":"碎股","TSYW.SI":"TESLA 3xLongSG261006","QLD":"纳指两倍做多ETF","CRSP":"CRISPR Therapeutics AG","PSQ":"纳指反向ETF","NVIW.SI":"NVDA 3xLongSG261006","SCD":"LMP Capital & Income Fund",".IXIC":"NASDAQ Composite","SQQQ":"纳指三倍做空ETF","QID":"纳指两倍做空ETF","USAW.SI":"AMZN 3xLongSG261006","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","LU1861558580.USD":"日兴方舟颠覆性创新基金B","TQQQ":"纳指三倍做多ETF","BK4139":"生物科技"},"translate_title":"为什么Editas Medicine，Inc.(EDIT)是最值得投资的CRISPR股票之一？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1,"EDIT":1,"SCD":1,".IXIC":0.9,"USJW.SI":0.6,"USAW.SI":0.6,"TSYW.SI":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NVIW.SI":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.\nThe pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital therapeutics, and artificial intelligence. Among the most exciting breakthroughs are gene therapy and gene editing, with CRISPR-Cas9 leading the charge. This remarkable tool, inspired by bacteria's natural defenses, acts like precise genetic scissors—faster, cheaper, and more accurate than other genome-editing methods.\nBack in 2014, CRISPR and its associated Cas proteins were mostly limited to academic research, generating a lot of excitement but seeming far from real-world applications. Just six years later, after earning a Nobel Prize, CRISPR began to make its way into over 20 clinical trials. The COVID-19 pandemic further demonstrated its potential, with CRISPR-based tests delivering quick and accurate virus detection, while experimental treatments explored its use against the virus—showcasing the technology’s incredible flexibility in tackling public health crises.\nThe CRISPR technology market is poised for explosive growth. Coherent Market Insights estimates it will be worth $3.64 billion in 2024 and climb to more than $12.46 billion by 2031, growing at an impressive annual rate of 19.2%. Cell and gene therapies are game-changing for treating certain cancers and rare diseases. As of 2024, there are 38 FDA-approved cell and gene therapy products, including six CAR-T cell therapies targeting cancers like lymphoma, leukemia, and multiple myeloma. Several gene therapies are also available for rare genetic disorders, such as spinal muscular atrophy and Duchenne muscular dystrophy. The industry's focus has evolved from simply proving these therapies work to optimizing their effectiveness, minimizing side effects, and broadening their applications.\nHowever, these therapies can come with eye-watering price tags—ranging from $400,000 to $2 million per dose. Although the sector has faced tough investment conditions since its boom in 2020 and 2021, there are signs of a rebound. Investments in the first half of 2024 reached $10.9 billion, surpassing 2019’s $9.8 billion, though still shy of the record $19.9 billion and $22.7 billion seen in 2020 and 2021. Funding dipped to $12.6 billion in 2022 and $11.7 billion in 2023. But there’s hope: Morgan Stanley suggests that Federal Reserve interest rate cuts could breathe new life into riskier assets like cell and gene therapies, aligning with a broader recovery in biotech.\nThe regulatory landscape for gene and regenerative therapies has also come a long way. In the U.S., the FDA has created clearer pathways for development, aided by the Regenerative Medicine Advanced Therapy (RMAT) designation, which speeds up review times and offers additional support to developers. Similarly, Europe has made strides with its guidelines for Advanced Therapy Medicinal Products (ATMPs). In 2017, the European Commission introduced a joint action plan to simplify processes for companies. While there’s still progress to be made, the push toward harmonized international regulations has made it easier for companies to secure approvals across multiple regions.\nOur Methodology\nTo identify the top 11 CRISPR stocks to invest in, we started by analyzing companies in the sector using ETF holdings and media coverage. We then narrowed down the list by focusing on top-performing stocks with the highest number of hedge fund investors, as tracked by Insider Monkey’s database of 900 hedge funds at the end of Q3 2024.\nAt Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\n A scientist looking into a microscope in a clinical lab setting, symbolizing the cutting edge research done by the biotech company. \nEditas Medicine, Inc. (NASDAQ:EDIT)\nNumber of Hedge Fund Holders: 23\nEditas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage biotechnology company developing gene-editing therapies using CRISPR technology to treat genetic disorders by modifying patients' genomes. The company’s lead candidate, EDIT-301, is in late-stage clinical trials for sickle cell disease (SCD) and beta-thalassemia.\nOn December 12, Editas Medicine, Inc. (NASDAQ:EDIT) announced a strategic pivot to focus on its in vivo CRISPR gene-editing programs, driven by promising preclinical results. The company aims to extend its cash runway into Q2 2027 and plans to demonstrate human proof of concept for its in vivo treatments within the next two years. Editas Medicine, Inc. (NASDAQ:EDIT) sees its in vivo gene-editing platform as a game-changer, with the potential to unlock new therapeutic possibilities and solidify its leadership in the field.\nSignificant updates on clinical development are not expected in the near term, with the next major insights anticipated in early 2025. At that time, the company is expected to outline additional potential indications for its CRISPR technology. Meanwhile, Editas has reported promising preclinical results in gene editing of hematopoietic stem cells (HSCs), showing potential for treating both sickle cell disease and beta-thalassemia.\nOverall EDIT ranks 7th on our list of the top CRISPR stocks to invest in. While we acknowledge the potential of EDIT as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than EDIT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.   \nREAD NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.   \nDisclosure: None. This article is originally published at Insider Monkey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2495508368"}